Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pauz.200700253 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.
CNS Drugs
January 2025
School of Medicine and Dentistry, Gold Coast Campus, Griffith University, Southport, QLD, 4222, Australia.
Background: Epstein-Barr virus (EBV) is implicated as a necessary factor in the development of multiple sclerosis (MS) and may also be a driver of disease activity. Although it is not clear whether ongoing viral replication is the driver for MS pathology, MS researchers have considered the prospect of using drugs with potential efficacy against EBV in the treatment of MS. We have undertaken scientific and lived experience expert panel reviews to shortlist existing licensed therapies that could be used in later-stage clinical trials in MS.
View Article and Find Full Text PDFMulti-Stakeholder Call to Action for the Future of Vaccine Post-Marketing Monitoring: Proceedings from the First Beyond COVID-19 Monitoring Excellence (BeCOME) Conference.
Drug Saf
January 2025
Pfizer (Worldwide Medical & Safety), New York, NY, USA.
Need for travel health clinic: A cross-sectional study among international travellers availing yellow fever vaccination in a teaching institution.
J Family Med Prim Care
December 2024
Department of Community Medicine, Seth G.S Medical College and KEM Hospital, Mumbai, Maharashtra, India.
Background: Traveller's health is one of the factors determining the success of his or her visit to the destination. The health aspects before, during and after travel are often neglected which may lead to untoward incidences during or after travel. Also, with the increase in national and international travel many emerging and re-emerging diseases are on the rise.
View Article and Find Full Text PDFHousehold transmission of SARS-CoV-2 in five US jurisdictions: Comparison of Delta and Omicron variants.
PLoS One
January 2025
COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Households are a significant source of SARS-CoV-2 transmission, even during periods of low community-level spread. Comparing household transmission rates by SARS-CoV-2 variant may provide relevant information about current risks and prevention strategies. This investigation aimed to estimate differences in household transmission risk comparing the SARS-CoV-2 Delta and Omicron variants using data from contact tracing and interviews conducted from November 2021 through February 2022 in five U.
View Article and Find Full Text PDFSummary of the National Advisory Committee on Immunization (NACI) Statement-Updated guidance on Imvamune in the context of a routine immunization program.
Can Commun Dis Rep
January 2025
Department of Medicine, University of Alberta, Edmonton, AB.
Background: Mpox is a viral illness related to smallpox. It can cause flu-like symptoms and a rash, and in severe cases, can lead to hospitalization or death. The Imvamune® vaccine offers protection against mpox.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!